In landmark international program, HTA agencies around the world access ICER's customisable COVID-19 cost-effectiveness model

ICER

9 October 2020 - Leveraging ICER’s new cloud-based Interactive Modeler platform, Quebec’s HTA agency has used the COVID-19 model to inform Ministerial recommendations on remdesivir; other HTA agencies and research groups in the United Kingdom, Australia, Canada and South Africa plan to access the model.

The Institute for Clinical and Economic Review (ICER) today announced a first-of-its-kind program that will enable all international health technology assessment (HTA) agencies to gain access to ICER’s cost-effectiveness models on a cloud-based platform that allows customization of model assumptions and inputs. 

The goal of this initiative is to enhance the transparency of HTA assessments around the world, enable access to ICER models for all HTA groups, including those from lower and middle income countries, and to enable the international HTA community to inform governmental decisions about drug pricing and coverage with economic model results that are rapidly available, based on the best available science, and locally tailored to reflect diverse health systems.

Read ICER Announcement

Michael Wonder

Posted by:

Michael Wonder